Full Text
PCN96 A TRIAL-BASED ASSESSMENT OF THE COST-UTILITY OF BEVACIZUMAB AND CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

Abstract

Authors

B Goulart S Ramsey

Back to Volume 13, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×